Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/assessing-tp53-status-in-human-tumours-to-evaluate-clinical-outcome-GT8ynQehfg
References (89)
-
A. Rosenthal, A. Ryan, R. Al-Jehani, A. Storey, C. Harwood, I. Jacobs (1998)
p53 codon 72 polymorphism and risk of cervical cancer in UKThe Lancet, 352
-
U. Moll, M. Laquaglia, J. Bénard, G. Riou (1995)
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.Proceedings of the National Academy of Sciences of the United States of America, 92 10
-
S. Dowell, P. Wilson, N. Derias, D. Lane, P. Hall (1994)
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.Cancer research, 54 11
-
W. El-Deiry, S. Kern, J. Pietenpol, K. Kinzler, B. Vogelstein (1992)
Definition of a consensus binding site for p53Nature Genetics, 1
-
B. Powell, R. Soong, B. Iacopetta, Ram Seshadri, Duncan Smith (2000)
Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 2
-
C. Kihara, Toyokazu Seki, Y. Furukawa, H. Yamana, Y. Kimura, Pepijn Schaardenburgh, K. Hirata, Yusuke Nakamura (2000)
Mutations in Zinc‐binding Domains of p53 as a Prognostic Marker of Esophageal‐cancer PatientsJapanese Journal of Cancer Research : Gann, 91
-
P. May, E. May (1999)
Twenty years of p53 research: structural and functional aspects of the p53 proteinOncogene, 18
-
Takashi Takahashi, M. Nau, I. Chiba, M. Birrer, R. Rosenberg, Michelle Vinocour, M. Levitt, H. Pass, A. Gazdar, J. Minna (1989)
p53: a frequent target for genetic abnormalities in lung cancer.Science, 246 4929
-
Jian Yu, Lin Zhang, P. Hwang, C. Rago, K. Kinzler, B. Vogelstein (1999)
Identification and classification of p 53-regulated genes -
T. Hashimoto, Y. Tokuchi, Moriaki Hayashi, Yasuhito Kobayashi, K. Nishida, Shin-ichi Hayashi, Yuichi Ishikawa, S. Tsuchiya, Ken Nakagawa, Jun-ichi Hayashi, Eiju Tsuchiya (1999)
p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.Cancer research, 59 21
-
Massimiliano Gentile, M. Jungeström, Karen Olsen, Peter Söderkvist, S. Wingren (1999)
p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation.European journal of cancer, 35 8
-
A. Børresen, T. Andersen, J. Eyfjörd, R. Cornelis, S. Thorlacius, Å. Borg, U. Johansson, C. Theillet, S. Scherneck, Susanne Hartman, C. Cornelisse, E. Hovig, P. Devilee (1995)
TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domainsGenes, 14
-
Y. Tomizawa, T. Kohno, T. Fujita, M. Kiyama, R. Saito, M. Noguchi, Y. Matsuno, S. Hirohashi, N. Yamaguchi, T. Nakajima, J. Yokota (1999)
Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinomaOncogene, 18
-
J. Nigro, S. Baker, A. Preisinger, J. Jessup, Richard Hosteller, Karen Cleary, Sandra Signer, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. Collins, Ainsley Weslon, R. Modali, C. Harris, B. Vogelstein (1989)
Mutations in the p53 gene occur in diverse human tumour typesNature, 342
-
E Kucera (1999)
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patientsEur. J. Cancer, 35
-
A Storey (1998)
p53 polymorphism and risk of cervical cancer: replyNature, 396
-
G. Beckman, R. Birgander, A. Själander, N. Saha, P.Å. Holmberg, A. Kivelä, L. Beckman (1994)
Is p53 polymorphism maintained by natural selection?Human heredity, 44 5
-
J. Schiller, Saptakatha Adak, R. Feins, S. Keller, W. Fry, R. Livingston, M. Hammond, B. Wolf, L. Sabatini, J. Jett, L. Kohman, D. Johnson (2001)
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
-
R. Erber, C. Conradt, N. Homann, C. Enders, M. Finckh, A. Dietz, H. Weidauer, F. Bosch (1998)
TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancerOncogene, 16
-
S. Kern, K. Kinzler, S. Baker, J. Nigro, V. Rotter, A. Levine, P. Friedman, C. Prives, B. Vogelstein (1991)
Mutant p53 proteins bind DNA abnormally in vitro.Oncogene, 6 1
-
E. Berns, I. Staveren, M. Look, M. Smid, J. Klijn, J. Foekens (1998)
Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.British Journal of Cancer, 77
-
M. Marin, C. Jost, L. Brooks, M. Irwin, J. O'Nions, J. Tidy, Nick James, J. McGregor, C. Harwood, I. Yulug, K. Vousden, M. Allday, B. Gusterson, S. Ikawa, P. Hinds, T. Crook, W. Kaelin (2000)
A common polymorphism acts as an intragenic modifier of mutant p53 behaviourNature Genetics, 25
-
Yunje Cho, S. Gorina, P. Jeffrey, N. Pavletich (1994)
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.Science, 265 5170
-
V. Skaug, D. Ryberg, E. Kure, M. Arab, L. Stangeland, A. Myking, A. Haugen (2000)
p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 3
-
J. Gong, A. Costanzo, Hong-Qiong Yang, G. Melino, W. Kaelin, M. Levrero, Jean Wang (1999)
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damageNature, 399
-
D. Bell, J. Varley, Tara Szydlo, D. Kang, D. Wahrer, K. Shannon, Marcie Lubratovich, S. Verselis, K. Isselbacher, J. Fraumeni, J. Birch, Frederick Li, J. Garber, D. Haber (1999)
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.Science, 286 5449
-
K. Ory, Y. Legros, Christelle Auguin, Thierry Soussil (1994)
Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.The EMBO Journal, 13
-
P. Hinds, C. Finlay, R. Quartin, Suzanne Baker, E. Fearon, Bert Vogelstein, A. Levine (1990)
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 1 12
-
F. Vega, P. Iniesta, T. Caldés, A. Sánchez, Jamie Lopez, C. Juan, E. Díaz-Rubio, A. Torres, J. Balibrea, M. Benito (1997)
p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer.British Journal of Cancer, 76
-
Kam-Bo Wong, B. Dedecker, Stefan Freund, Mark Proctor, M. Bycroft, A. Fersht (1999)
Hot-spot mutants of p53 core domain evince characteristic local structural changes.Proceedings of the National Academy of Sciences of the United States of America, 96 15
-
S. Baker, E. Fearon, J. Nigro, S. Hamilton, A. Preisinger, J. Jessup, P. Vantuinen, D. Ledbetter, D. Barker, Y. Nakamura, Raymond White, B. Vogelstein (1989)
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.Science, 244 4901
-
A. Storey, Miranda Thomas, A. Kalita, C. Harwood, D. Gardiol, F. Mantovani, J. Breuer, I. Leigh, G. Matlashewski, L. Banks (1998)
p53 polymorphism and risk of cervical cancerNature, 396
-
O. Halevy, D. Michalovitz, M. Oren (1990)
Different tumor-derived p53 mutants exhibit distinct biological activities.Science, 250 4977
-
G. Blandino, A. Levine, M. Oren (1999)
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapyOncogene, 18
-
T. Soussi, Karim Dehouche, C. Béroud (2000)
p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesisHuman Mutation, 15
-
G. Rotman, Y. Shiloh (1999)
ATM: A mediator of multiple responses to genotoxic stressOncogene, 18
-
A. Yang, F. McKeon (2000)
p63 and p73: p53 mimics, menaces and moreNature Reviews Molecular Cell Biology, 1
-
M. Takahashi, H. Tonoki, M. Tada, H. Kashiwazaki, K. Furuuchi, J. Hamada, Yasunori ujioka, Yuji Sato, Hiromasa Takahashi, S. Todo, N. Sakuragi, T. Moriuchi (2000)
Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancersInternational Journal of Cancer, 89
-
J. Milner, E. Medcalf (1991)
Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformationCell, 65
-
M. Levrero, V. Laurenzi, Antonio Costanzo, J. Gong, Gerry Melino, Jean Wang (1999)
Structure, function and regulation of p63 and p73Cell Death and Differentiation, 6
-
Ole Clausen, R. Lothe, A. Børresen-Dale, P. Angelis, Ying Chen, T. Rognum, G. Meling (1998)
Association of p53 Accumulation With TP53 Mutations, Loss of Heterozygosity at 17p13, and DNA Ploidy Status in 273 Colorectal CarcinomasDiagnostic Molecular Pathology, 7
-
Arndt Hartmann, H. Blaszyk, J. Kovach, S. Sommer (1997)
The molecular epidemiology of p53 gene mutations in human breast cancer.Trends in genetics : TIG, 13 1
-
M. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller, Ximena Opitz-Araya, R. Mccombie, J. Herman, W. Gerald, Y. Lazebnik, C. Cordon-Cardo, S. Lowe (2001)
Inactivation of the apoptosis effector Apaf-1 in malignant melanomaNature, 409
-
A. Bullock, J. Henckel, A. Fersht (2000)
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapyOncogene, 19
-
I. Zehbe, Gianfranco Voglino, Erik Wilander, H. Delius, Antonella Marongiu, Lutz Edler, Fritz Klimek, Sonja Andersson, Massimo Tommasino (2001)
p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development.Cancer research, 61 2
-
S. Geisler, P. Lønning, T. Aas, H. Johnsen, Ø. Fluge, D. Haugen, J. Lillehaug, L. Akslen, A. Børresen-Dale (2001)
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.Cancer research, 61 6
-
S. Ikawa, Akira Nakagawara, Yoji Ikawa (1999)
p53 family genes: structural comparison, expression and mutationCell Death and Differentiation, 6
-
R. Agami, G. Blandino, M. Oren, Y. Shaul (1999)
Interaction of c-Abl and p73α and their collaboration to induce apoptosisNature, 399
-
H. Goh, J. Yao, Duncan Smith (1995)
p53 point mutation and survival in colorectal cancer patients.Cancer research, 55 22
-
S. Strano, E. Munarriz, M. Rossi, Barbara Cristofanelli, Y. Shaul, L. Castagnoli, A. Levine, A. Sacchi, G. Cesareni, M. Oren, G. Blandino (2000)
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73*The Journal of Biological Chemistry, 275
-
S. Rowan, R. Ludwig, Y. Haupt, S. Bates, Xin Lu, M. Oren, K. Vousden (1996)
Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant.The EMBO Journal, 15
-
C. Kostic, P. Shaw (2000)
Isolation and characterization of sixteen novel p53 response genesOncogene, 19
-
K. Hibi, B. Trink, M. Patturajan, W. Westra, O. Caballero, D. Hill, E. Ratovitski, J. Jen, D. Sidransky (2000)
AIS is an oncogene amplified in squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America, 97 10
-
E. Berns, J. Foekens, R. Vossen, M. Look, P. Devilee, S. Henzen‐Logmans, I. Staveren, W. Putten, M. Inganäs, M. Gelder, C. Cornelisse, C. Claassen, H. Portengen, B. Bakker, J. Klijn (2000)
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.Cancer research, 60 8
-
Tim Crook, D. Wrede, John Tidy, K Vousden, John Tidy, W. Mason, D. Evans (1992)
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumoursThe Lancet, 339
-
J. Gu, H. Kawai, D. Wiederschain, Z. Yuan (2001)
Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.Cancer research, 61 4
-
M. Harvey, H. Vogel, D. Morris, A. Bradley, A. Bernstein, L. Donehower (1995)
A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient miceNature Genetics, 9
-
M. Stolzenberg, L. Brugières, M. Gardes, F. Dessarps-Freichey, A. Chompret, B. Bressac, G. Lenoir, C. Bonaïti‐pellié, J. Lemerle, J. Feunteun (1994)
Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.Oncogene, 9 10
-
S. Lanham, I. Campbell, P. Watt, R. Gornall (1998)
p53 polymorphism and risk of cervical cancerThe Lancet, 352
-
A. Storey, Miranda Thomas, A. Kalita, C. Harwood, D. Gardiol, F. Mantovani, J. Breuer, I. Leigh, G. Matlashewski, L. Banks (1998)
Role of a p53 polymorphism in the development of human papilloma-virus-associated cancerNature, 393
-
Jian Yu, Lin Zhang, P. Hwang, C. Rago, K. Kinzler, B. Vogelstein (1999)
Identification and classification of p53-regulated genes.Proceedings of the National Academy of Sciences of the United States of America, 96 25
-
D. Dittmer, Sibani Pati, G. Zambetti, Shelley Chu, A. Teresky, M. Moore, C. Finlay, A. Levine (1993)
Gain of function mutations in p53Nature Genetics, 4
-
S. Geisler, P. Lønning, T. Aas, H. Johnsen, Ø. Fluge, D. Haugen, J. Lillehaug, L. Akslen, A. Børresen-Dale (2001)
Influence of TP 53 Gene Alterations and c-erbB2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer 1 -
S. Ahrendt, S. Halachmi, J. Chow, Li Wu, N. Halachmi, Stephen Yang, S. Wehage, J. Jen, D. Sidransky (1999)
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array.Proceedings of the National Academy of Sciences of the United States of America, 96 13
-
K. Kannan, N. Amariglio, G. Rechavi, Jasmine Jakob-Hirsch, I. Kela, N. Kaminski, G. Getz, E. Domany, D. Givol (2001)
DNA microarrays identification of primary and secondary target genes regulated by p53Oncogene, 20
-
J. Oliner, K. Kinzler, P. Meltzer, D. George, B. Vogelstein (1992)
Amplification of a gene encoding a p53-associated protein in human sarcomasNature, 358
-
S. Kern, J. Pietenpol, S. Thiagalingam, A. Seymour, K. Kinzler, B. Vogelstein (1992)
Oncogenic forms of p53 inhibit p53-regulated gene expressionScience, 256
-
Paul Smith, S. Crossland, G. Parker, P. Osin, L. Brooks, J. Waller, Elizabeth Philp, M. Crompton, B. Gusterson, M. Allday, T. Crook (1999)
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functionsOncogene, 18
-
T. Aas, A. Børresen, S. Geisler, B. Smith-Sørensen, H. Johnsen, J. Varhaug, L. Akslen, P. Lønning (1996)
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 2
-
A. Bullock, A. Fersht (2001)
Rescuing the function of mutant p53Nature Reviews Cancer, 1
-
Renbin Zhao, K. Gish, M. Murphy, Yuxin Yin, D. Notterman, William Hoffman, E. Tom, D. Mack, A. Levine (2000)
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.Genes & development, 14 8
-
Karen Vousden (2000)
Minireviewp 53 : Death Star able to induce the defensive p 53 response to oncogene -
B. Vogelstein, D. Lane, A. Levine (2000)
Surfing the p53 networkNature, 408
-
Elisabeth Kucera, P. Speiser, M. Gnant, L. Szabó, H. Samonigg, H. Hausmaninger, Martina Mittlböck, M. Fridrik, Michael Seifert, Ernst Kubista, Angelika Reiner, R. Zeillinger, R. Jakesz (1999)
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.European journal of cancer, 35 3
-
Jiyong Zhao, Jiyong Zhao, Brian Kennedy, Brandon Lawrence, D. Barbie, A. Matera, Jonathan Fletcher, Ed Harlow (2000)
NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription.Genes & development, 14 18
-
G. Selivanova, V. Iotsova, İ. Okan, M. Fritsche, M. Ström, B. Groner, R. Grafström, K. Wiman (1997)
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domainNature Medicine, 3
-
J. Varley, C. Attwooll, G. White, G. McGown, M. Thorncroft, A. Kelsey, M. Greaves, J. Boyle, J. Birch (2001)
Characterization of germline TP53 splicing mutations and their genetic and functional analysisOncogene, 20
-
E. Berns, J. Foekens, R. Vossen, M. Look, P. Devilee, S. Henzen‐Logmans, I. Staveren, W. Putten, M. Inganäs, M. Gelder, C. Cornelisse, C. Claassen, H. Portengen, B. Bakker, J. Klijn (2000)
Complete Sequencing of TP 53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer 1 -
T. Tokino, Y. Nakamura (2000)
The role of p53-target genes in human cancer.Critical reviews in oncology/hematology, 33 1
-
P. Chappuis, A. Estreicher, B. Dieterich, H. Bonnefoi, Michèle Otter, A. Sappino, R. Iggo (1999)
Prognostic significance of p53 mutation in breast cancer: Frequent detection of non‐missense mutations by yeast functional assayInternational Journal of Cancer, 84
-
P. Crémoux, A. Salomon, S. Liva, R. Dendale, Brigitte Bouchind'homme, Emmanuel Martin, X. Sastre-Garau, Henri Magdelenat, Alain Fourquet, Thierry Soussi (1999)
p53 mutation as a genetic trait of typical medullary breast carcinoma.Journal of the National Cancer Institute, 91 7
-
C. Gaiddon, M. Lokshin, Jinwoo Ahn, Tingting Zhang, C. Prives (2001)
A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core DomainMolecular and Cellular Biology, 21
-
K. Forrester, Shawn Lupold, V. Ott, C. Chay, V. Band, X. Wang, C. Harris (1995)
Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.Oncogene, 10 11
-
Cheng‐long Huang, T. Taki, M. Adachi, T. Konishi, M. Higashiyama, M. Miyake (1998)
Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancerOncogene, 16
-
Roseanne Hansen, M. Oren (1997)
p53; from inductive signal to cellular effect.Current opinion in genetics & development, 7 1
-
A. Børresen-Dale, R. Lothe, G. Meling, Pierre Hainaut, T. Rognum, Eva Skovlund (1998)
TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 1
-
E. Ratovitski, M. Patturajan, K. Hibi, B. Trink, K. Yamaguchi, D. Sidransky (2001)
p53 associates with and targets ΔNp63 into a protein degradation pathwayProceedings of the National Academy of Sciences of the United States of America, 98
-
Geng-Hung Liu, T. McDonnell, Roberto Luna, Roberto Luna, M. Kapoor, B. Mims, A. El-Naggar, G. Lozano (2000)
High metastatic potential in mice inheriting a targeted p53 missense mutation.Proceedings of the National Academy of Sciences of the United States of America, 97 8
-
KH Vousden (2000)
p53. Death starCell, 103
- Publisher
- Springer Journals
- Copyright
- Copyright © 2001 by Nature Publishing Group
- Subject
- Biomedicine; Biomedicine, general; Cancer Research
- ISSN
- 1474-175X
- eISSN
- 1474-1768
- DOI
- 10.1038/35106009
- Publisher site
- See Article on Publisher Site
Abstract
TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?
Journal
Nature Reviews Cancer – Springer Journals
Published: Dec 1, 2001